openPR Logo
Press release

Migraine - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | AbbVie Inc, Achelios Therapeutics Inc, AEON Biopharma Inc, AgoneX Biopharmaceuticals In

02-23-2023 06:56 AM CET | Health & Medicine

Press release from: Global Insight Services

Migraine

Migraine

As per Global Insight services' assessment, about 50+ prominent pharma and biotech giants are working on 50+ drugs in the Migraine - pipeline landscape globally. Migraine Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies : https://www.globalinsightservices.com/request-sample/GIS31182

Migraine is a neurological disorder that is associated with recurrent headaches. The headache is characterized by affecting one side of the head, pulsating, moderate to severe in intensity which last for few hours to three days.

The underlying cause of migraine is unknown. It is believed that, migraine may be due to a mixture of environmental triggers and genetical factors. Change in hormonal levels during puberty may also affect the cause of migraine. Triggering factors include fatigue, certain foods, alcohol, and whether. Psychological stress quoted to be a risk factor.

Report Highlights

Global Insight Service's, Migraine - Drug Pipeline Landscape, 2023 report provides an overview of the Migraine pipeline drugs. This report covers detailed insights on Migraine drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Migraine pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Read more about Migraine Pipeline Insight here: https://www.globalinsightservices.com/reports/migraine-drug-pipeline-landscape-2022

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Key Players

• AbbVie Inc
• Achelios Therapeutics Inc
• AEON Biopharma Inc
• AgoneX Biopharmaceuticals Inc
• Allodynic Therapeutics LLC
• Amgen Inc
• Amneal Pharmaceuticals Inc
• AOBiome LLC
• Arovella Therapeutics Ltd
• Asarina Pharma AB
• Astrocyte Pharmaceuticals Inc
• Axsome Therapeutics Inc
• Better Life Pharmaceuticals Inc
• Biohaven Pharmaceutical Holding Company Ltd
• Blackthorn Therapeutics Inc

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31182

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -

- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail:info@globalinsightservices.com
Phone: +1-833-761-1700
Website:https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Migraine - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | AbbVie Inc, Achelios Therapeutics Inc, AEON Biopharma Inc, AgoneX Biopharmaceuticals In here

News-ID: 2944728 • Views:

More Releases from Global Insight Services

Hydrogen Generation Market Poised to Grow from $155.5 Billion in 2024 to $410.6 Billion by 2034 at 10.2% CAGR | Leading Key Players Analysis & Overall Study Report
Hydrogen Generation Market Poised to Grow from $155.5 Billion in 2024 to $410.6 …
The Hydrogen Generation Market is set to experience remarkable growth, expanding from $155.5 billion in 2024 to an estimated $410.6 billion by 2034, registering a robust CAGR of approximately 10.2%. Hydrogen generation involves producing and supplying hydrogen through various techniques, including steam methane reforming, electrolysis, and coal gasification. This market plays a pivotal role in supporting industries seeking cleaner energy solutions, spanning transportation, power generation, and industrial processes. As the
Identity and Access Management Market Poised to Grow from $15.9 Billion in 2024 to $38.2 Billion by 2034 at 9.2% CAGR | Leading Players Analysis & Overall Study Report
Identity and Access Management Market Poised to Grow from $15.9 Billion in 2024 …
The Identity & Access Management (IAM) market is poised for substantial growth, expanding from an estimated $15.9 billion in 2024 to $38.2 billion by 2034 at a robust CAGR of approximately 9.2%. IAM encompasses systems, tools, and policies that manage digital identities and regulate user access within organizations. This includes solutions such as authentication, single sign-on, identity governance, and privileged access management. These technologies are essential for ensuring security, compliance,
Endoscopy Devices Market Is Anticipated To Expand From $14.5 Billion In 2024 To $26.3 Billion By 2034,
Endoscopy Devices Market Is Anticipated To Expand From $14.5 Billion In 2024 To …
Market Overview The Endoscopy Devices Market is playing an increasingly important role in modern healthcare by supporting minimally invasive diagnostic and surgical procedures. These devices, which include endoscopes, visualization systems, and complementary instruments, allow physicians to examine internal organs with precision, leading to faster diagnoses, less trauma for patients, and improved recovery times. As the global burden of chronic diseases rises, the demand for such technologies continues to expand. Additionally, advancements
Sustainable Fashion Market Is Anticipated To Expand From $13.8 Billion In 2024 To $44.1 Billion By 2034
Sustainable Fashion Market Is Anticipated To Expand From $13.8 Billion In 2024 T …
Market Overview The Sustainable Fashion Market has gained remarkable momentum in recent years as consumers, brands, and policymakers increasingly recognize the need for eco-friendly and socially responsible alternatives in the fashion industry. Unlike conventional fashion, which is often criticized for its high carbon footprint and exploitative labor practices, sustainable fashion emphasizes the use of organic, recycled, and biodegradable materials, along with ethical supply chains and fair trade principles. This shift represents

All 5 Releases


More Releases for Migraine

Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share? The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size? The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market? The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes. Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market. The objectives outlined in the report are multifaceted and aimed at offering a comprehensive
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases. The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs. Get Access to TOC /